Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.

The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therapy), while extended RAS and BRAF testing is standard in metastatic colorectal cancer to predict benefits from epidermal growth factor receptor (EGFR)-targeted therapies. Mismatch repair (MMR) or microsatellite instability (MSI) testing is standard for all advanced GI cancers to predict benefits from pembrolizumab and in metastatic colorectal cancer, nivolumab with or without ipilimumab.

Determination of biodegradation rates for surfactants and a fatty alcohol in aerobic sediment using a simplified test system.

The development of specific regulatory persistence criteria and a growing need to conduct risk assessments in sediment have increased the need to better understand fate in this compartment. A simplified test approach was developed to assess the fate of chemicals in aerobic sediments and used to evaluate the biodegradation of (14) C-labeled representative analogs of alcohol sulfate, alcohol ethoxylate, alcohol ethoxy sulfate, linear alkylbenzene sulfonate, and tetradecanol in 2 different sediments. The method provides kinetic data on primary and ultimate biodegradation in sediments as well as information on biodegradation pathways and metabolites.